The future of the global multivalent pneumococcal conjugate vaccine market looks promising with opportunities in the hospital, outpatient center markets.
- Within the type category, 24 price is expected to witness the highest growth over the forecast period due to the 24-valent vaccine has higher potency than the 13, 20, and 23-valent vaccines.
- Within the application category, hospital is expected to witness the higher growth due to it is frequently used in advanced medical situations.
- In terms of regions, North America is expected to witness the highest growth over the forecast period due to it requires an advanced medical infrastructure and a large pharmaceutical industry.
Emerging Trends in Multivalent Pneumococcal Conjugate Vaccine Market
Multivalent pneumococcal conjugate vaccine market is expected to transition from routine pediatric coverage to extended, age inclusive protection. From 2025 to 2027, product line, national immunization schedules, manufacturing capacity, and serotype surveillance will determine market competitiveness. Lucintel expects a market shift toward more valent vaccines, enhanced adult vaccination, and stronger evidence towards vaccine protection and health economics.- Higher Valency Protection: Illustrates Pfizer’s PREVNAR 20, which recently expanded vaccine protection for use in children beyond legacy vaccines, while 20-valent vaccines target even greater serotype protection; this example will influence procurement as invasive pneumococcal disease begins to reflect serotype replacement.
- Adult Immunization Expansion: Widens the target population as the U.S. now recommends PCV20, PCV21, or vaccination as a series for adults 50 years and older; pharmacies and primary care will be the primary care demand channels for the next 3 to 5 years.
- Schedule Simplification: Manufacturers stand to gain a competitive advantage as simplified vaccine schedules for adults will encourage easier single dose regimens.; countries aim for improved real world vaccination rates.
- Regional Manufacturing Diversification: UNICEF’s 2025 supply relies on maintaining reliable vaccine supply and price sensitive procurement while production capacity focuses on technology transfer; this will bring improved regional capacity, reduce supply shocks, and improve participation in tenders up to 2030.
- Evidence-led Premiumization: As health agencies evaluate value for different vaccine alternatives, beyond assessing cost per unit (price), new vaccines with substantial reductions in hospitalizations and antimicrobial resistance infections should retain value in contracted services.
Recent Developments in the Multivalent Pneumococcal Conjugate Vaccine Market
Between 2025 and 2027, serotype coverage will continue to expand along with pediatric labels and supply aimed at national vaccine programs. Lucintel suggests steady competition between established formulations and pneumococcal conjugate vaccines. From now through 2027, procurement decisions will be based on multiple factors such as disease burden, cost to manufacture, and supply.- Pediatric Label: In April 2025, the U.S. Food and Drug Administration (FDA) approved a pediatric label of Pfizer's Prevnar 20 (from six weeks to 17 years). Publicly funded programs would have to consider price and schedule changes to eliminate lower valency vaccines in order to replace Prevnar 20.
- Competitive Adult Market Position: In June 2024 the U.S. FDA approved the serotype of GSK’s CAPVAXIVE (21-valent), and GSK continued adult product broadening in 2025. GSK’s positioning indicates that, unlike competitors, they are not pursuing valency target immune protection and are focusing instead on adult disease.
- Government Procurement: The Alliance for Vaccine Initiative (Gavi) has committed over US$4 billion for 2026-2030, and Gavi has focused on lower income and lower resource countries for pneumococcal vaccine procurement. This would enable a greater number of tenders to be met, and suppliers would be forced to offer more cost effective doses.
- Scalable Manufacturing: The Serum Institute of India has begun building additional capacity in Pune for the production of pneumococcal vaccines to be prepared for increased demand for a broader supply of pneumococcal vaccines over the next three years. This will meet the need for more supply to lessen the burden of reliance on a few large multinational corporations to meet supply needs.
- Serotype Surveillance Partnerships: WHO and national public health agencies are working to build post-introduction surveillance capacity as disease patterns evolve with serotype replacement. The data generated in 2025 will direct future conjugate designs, influence reimbursement, and clarify the value to be gained by manufacturers for adding serotypes or refining antigen selection.
Strategic Growth Opportunities in the Multivalent Pneumococcal Conjugate Vaccine Market
From 2024 to 2026, prevention of pneumococcal disease will move from infant-only prevention to more comprehensive, risk-based prevention. The combination of new serotypes, aging populations, procurement reforms, and domestic vaccine goals is expanding the market potential. According to Lucintel, there is space for manufacturers to deliver prevention with greater breadth.- Expansion of The Pediatric Schedule: Pfizer’s Prevnar 20 received pediatric approval in the U.S. in April 2025, adding coverage for 20 serotypes. Broader routine schedules will lead to a shift to higher valency products in procurement as countries are undertaking reviews of their immunization programs.
- Risk-based Vaccination of Adults: The U.S. CDC’s 2024 recommendation for risk based pneumococcal vaccination of adults aged >=50 improved this market and by January 2025, target market population was estimated to exceed 100 million. Pharmacies and chronic care providers will provide ongoing demand outside childhood tenders.
- Geographic Market Expansion: With Gavi’s 2025-2029 strategy, 50% co-financing for vaccine programs, there will be greater access to pneumococcal vaccines in underserved markets. Local market needs and tiered pricing will encourage entry of pneumococcal vaccines in the market in the next five years.
- Premium Combination Products: In 2024, Pfizer’s Prevnar family of vaccines brought in revenues greater than $6 billion, demonstrating their commitment to funding a range of innovative products. Where private health care and employer programs are concerned, combination products with the potential for a reduced number of visits would command a greater incentive.
- Sustainable Manufacturing: The vaccine industry in India manufactured over 2.5 billion doses in 2024, showing their position in lower cost supply. Manufacturers that focus on reducing the use of single use plastics, energy use or cold chain burden will be prioritized in public procurement tenders and international procurement.
Multivalent Pneumococcal Conjugate Vaccine Market Drivers and Challenges
The elements affecting the growth of the multivalent pneumococcal conjugate vaccine market are technological, economic, demographic, and regulatory factors. Increasing risks of invasive pneumococcal disease, an aging population, and increased vaccination and modernized vaccine platforms are factors driving demand for this vaccine. Manufacturing costs, demand vs. supply, affordability, and constantly changing recommendations are all factors contributing to the constraints of this vaccine. Market struggles as Lucintel indicates that accessibility, safety, and sustainability of production need to be considered for broader serotype coverage to prevail in the developed and developing health care systems.The factors responsible for driving this market include:
- Broad Serotype Coverage: Multivalent vaccines offer protection against multiple pneumococcal strains, thus improving their value as replacing serotypes decreases the effectiveness of previously used vaccines. In January 2025, the U.S. adult recommendations included vaccines of up to 21 serotypes. Broader protection will lead health care systems to replace lower valency products in the next 3 to 5 years.
- Increasing Disease Burden: Pneumonia, meningitis, and bloodstream infections are significant to infants, older adults, and other immunosuppressed individuals. In February 2025, the WHO still considered pneumococcal disease responsible for at least 300,000 deaths of children less than 5 years. Continued disease will give sustained demand for vaccination and support for extended and more comprehensive national programs.
- Extending Immunization Programs: Governments will include older adults, high-risk, and underserved constituencies in pneumococcal vaccination programs. Gavi-supported programs in 2025 continued targeting countries with adult immunization coverage < 80%. Public procurement and catch-up campaigns over the next 3-5 years will further penetrate and enhance market scope.
- Advances in Product Development: Combinatorial schedules and increased antigen loading in addition to use of carrier proteins, will improve performance and convenience of vaccine administration. Clinical trials in 2025 continued the development of conjugate vaccines that cover over 20 serotypes. Addressing serotype replacement and improving stabilization and shelf life of vaccines will enable manufacturers to compete successfully for recommendations and procurement.
- Enhanced Manufacturing: Improved fermentation, conjugation, and quality assurance will increase production, reduce waste, and lower costs. In 2025, manufacturers continued construction of new facilities designed to produce multivalent vaccines with 20 or more antigens. Manufacturing efficiency will be even more important for reducing costs, stabilizing supply, and responding to increasing demand.
The challenges facing this market include:
- High Development and Production Costs: Production and delivery of multivalent conjugate vaccines is both complex and expensive, requiring special antigen and carrier-protein manufacture, testing, and cold-chain logistics. In 2025, the quality control hurdles for the release of vaccines against 20 or more serotypes continued. Development costs remain a major barrier to COVID-19 vaccines in developing countries and will also likely be a significant barrier to broadening immunization to adults, as scale economies will take another 3-5 years to improve access.
- Regulatory and Clinical Complexity: Because protecting against multiple serotypes requires larger trials, longer follow-up, and more extensive regulatory work, demand is generated for consistent, specific recommendations by major markets. By July 2025, different recommendations across markets resulted in fragmented recommendations with variations in targeted groups and dosage. Disparate regulations increase the costs of development and slow entry to new markets, hindering the speed of expansion to new global markets.
- Supply Chain and Access Constraints: Several factors including unbalanced procurement, refrigerated storage, and the use of specialized raw materials can affect vaccine availability. By August 2025, coverage gaps remained for nearly 20 million children, despite efforts to close the immunization gap. These factors will remain significant for the next 3 to 5 years unless there is an improvement in regional production, financing, and delivery of resources.
List of Multivalent Pneumococcal Conjugate Vaccine Market Companies
Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies multivalent pneumococcal conjugate vaccine market companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base.Some of the multivalent pneumococcal conjugate vaccine market companies profiled in this report include:
- Merck Sharp & Dohme Corp
- Pfizer
- Cansino Bio
- Serum Institute Of India Pvt. Ltd.
- Shanghai Weizhou Biotechnology Co.
Multivalent Pneumococcal Conjugate Vaccine Market by Segment
The study includes a forecast for the global multivalent pneumococcal conjugate vaccine market by type, application, and region.Type [Value ($B) from 2019 to 2035]:
- 13 Price
- 20 Price
- 23 Price
- 24 Price
Application [Value ($B) from 2019 to 2035]:
- Hospital
- Outpatient Center
- Others
Region [Value ($B) from 2019 to 2035]:
- North America
- Europe
- Asia Pacific
- The Rest of the World
Country Wise Outlook for the Multivalent Pneumococcal Conjugate Vaccine Market
The reshaping of the multivalent pneumococcal conjugate vaccine market is the result of diverse factors such as the implementation of broader adult immunization policies, the introduction of higher valency vaccines, and the localization of manufacturing. During the period 2025 to 2027, national procurement and regulatory progress will be more important than the size of the pipeline announced. According to the latest assessment by Lucintel, the above-mentioned factors call for an intensive analysis on a country by country basis.- United States: Product diversification will be the predominant activity during this period. In June 2025, the CDC continued to advise the use of a single dose of PCV-21 (CAPVAXIVE) for adults 50 years and older, along with the use of PCV-20; Pfizer is also developing next generation conjugate vaccines. The adult population will gain a greater immunization focus during this period due to the policy and the resulting demand for products with higher valency in pharmacies, hospitals, and other sectors of the public vaccine program.
- China: During this period, the supply of vaccines will be policy oriented. The National Medical Products Administration of China continued to review native pneumococcal vaccines, and supported manufacturers in increasing production of commercial vaccines. Sinovac also has ongoing conjugate vaccines in its pipeline. During the next three to five years, public procurement will have an increased effect on domestic manufacture of vaccines.
- Germany: The Standing Committee on Vaccination continues to develop its recommendations for adult pneumococcal vaccination and the use of PCV20 in high-risk populations. Meanwhile, BioNTech and other companies began developing more sophisticated vaccine platforms in Europe. By January 2025, German national vaccination recommendations covered more than 20 million adults aged 60 and older. The Formal recommendations and large insured populations are influencing procurement and manufacture priorities.
- India: The government’s aim of increased adult immunization and the expanded domestic immunization program is supported by the continued supply of PNEUMOSIL by the Serum Institute of India to Gavi-supported programs. Since the vaccine has WHO prequalification, it can be used to immunize more than 70 countries. This production will support the goal of increasing adult immunization and enhance India’s position as a global supplier.
- Japan: In the absence of licensure for Adult CAPVAXIVE by MSD, Japan continued routine pneumococcal vaccination in older adults. Starting April 2025, the Japanese national program included adults ages 65 and older, as well as adults ages 60-64 with special conditions. Wider adult recommendations will influence procurement and influence manufacturers to pursue higher-valent vaccines in the adult market.
Features of the Global Multivalent Pneumococcal Conjugate Vaccine Market
- Market Size Estimates: multivalent pneumococcal conjugate vaccine market size estimation in terms of value ($B).
- Trend and Forecast Analysis: Market trends (2019 to 2026) and forecast (2027 to 2035) by various segments and regions.
- Segmentation Analysis: multivalent pneumococcal conjugate vaccine market size by type, application, and region in terms of value ($B).
- Regional Analysis: multivalent pneumococcal conjugate vaccine market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
- Growth Opportunities: Analysis of growth opportunities in different type, application, and regions for the multivalent pneumococcal conjugate vaccine market.
- Strategic Analysis: This includes M&A, new product development, and competitive landscape of the multivalent pneumococcal conjugate vaccine market.- Analysis of competitive intensity of the industry based on Porter’s Five Forces model.
This report answers the following 11 key questions:
Q.1. What are some of the most promising, high-growth opportunities for the multivalent pneumococcal conjugate vaccine market by type (13 price, 20 price, 23 price, and 24 price), application (hospital, outpatient center, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?Q.2. Which segments will grow at a faster pace and why?
Q.3. Which region will grow at a faster pace and why?
Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
Q.5. What are the business risks and competitive threats in this market?
Q.6. What are the emerging trends in this market and the reasons behind them?
Q.7. What are some of the changing demands of customers in the market?
Q.8. What are the new developments in the market? Which companies are leading these developments?
Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
Q.11. What M&A activity has occurred in the last 8 years and what has its impact been on the industry?
This product will be delivered within 1-3 business days.
Table of Contents
Companies Mentioned
- Merck Sharp & Dohme Corp
- Pfizer
- Cansino Bio
- Serum Institute Of India Pvt. Ltd.
- Shanghai Weizhou Biotechnology Co.
Methodology
The analyst has been in the business of market research and management consulting since 2000 and has published over 600 market intelligence reports in various markets/applications and served over 1,000 clients worldwide. Each study is a culmination of four months of full-time effort performed by the analyst team. The analysts used the following sources for the creation and completion of this valuable report:
- In-depth interviews of the major players in the market
- Detailed secondary research from competitors’ financial statements and published data
- Extensive searches of published works, market, and database information pertaining to industry news, company press releases, and customer intentions
- A compilation of the experiences, judgments, and insights of professionals, who have analyzed and tracked the market over the years.
Extensive research and interviews are conducted in the supply chain of the market to estimate market share, market size, trends, drivers, challenges and forecasts.
Thus, the analyst compiles vast amounts of data from numerous sources, validates the integrity of that data, and performs a comprehensive analysis. The analyst then organizes the data, its findings, and insights into a concise report designed to support the strategic decision-making process.

LOADING...

